Key Highlights

  • Quarterly Revenue at Veracyte (NASDAQ:VCYT) reached USD 151.8 million, a 15% gain, yet the 2026 testing revenue range was lowered, and a single market listing recorded a 54.30% drop on November 5, 2026.
  • Revenue at Natera (NASDAQ:NTRA) climbed 34.1% to USD 794.0 million, and its 2026 forecast now spans USD 3.005 billion to USD 3.035 billion, though after-hours shares slipped 16.15%.
  • Amylyx Pharmaceuticals (NASDAQ:AMLX) repeated the LUCIDITY finding of a 55% decrease in Level 2 and Level 3 hypoglycemic events, and ended September with USD 768.1 million of cash, equivalents and marketable securities.
  • The 2026 earnings-from-operations forecast at Oscar Health (NYSE:OSCR) moved up to between USD 850 million and USD 950 million, previously USD 600 million to USD 800 million, the third raise of the year.

Veracyte (NASDAQ:VCYT): Revenue Gain Overshadowed by a Narrower Testing Outlook

Veracyte (NASDAQ:VCYT) published third-quarter results on November 4, 2026, and on November 5 a market listing displayed a regular-session decline of 54.30%, or about 54%. That number comes from a single listing and is therefore handled as reported rather than confirmed. Revenue expanded 15% to USD 151.8 million from USD 131.9 million, with Net Income of USD 31.5 million and adjusted EBITDA of USD 41.2 million. Leadership reduced the 2026 testing revenue range to USD 571 million through USD 573 million from a previous USD 576 million through USD 582 million, a midpoint reduction of nearly USD 7 million (own arithmetic). The firm sells genomic tests that inform cancer care, and its largest product, Decipher Prostate, generated USD 92.3 million, up 12%, across roughly 29,900 tests. Since reimbursement is paid per test, diagnostics shares frequently track test volume. A published wrap said preliminary 2027 guidance fell well short of consensus and that a research firm had downgraded the stock, yet the release from the company included no 2027 numbers, leaving the downgrade unverified. Liquidity stood at USD 370.5 million in cash and short-term investments, and the 27.2% adjusted EBITDA Margin suggests the selloff centered on expectations for later growth, an inference.

Natera (NASDAQ:NTRA): Raised Full-Year Range Versus a Reported Chief Executive Switch

Natera (NASDAQ:NTRA) released third-quarter figures on November 5, 2026, showing revenue of USD 794.0 million, a 34.1% advance from USD 592.2 million. Management raised the full-year revenue range to USD 3.005 billion through USD 3.035 billion from USD 2.850 billion through USD 2.910 billion, which equates to a USD 140 million increase at the midpoint. Net loss shrank to USD 59.9 million, equal to USD 0.42 per share, versus USD 87.5 million previously, roughly a 32% improvement (own arithmetic). Thursday's after-hours session showed shares off 16.15%, a move that could narrow or deepen before the next regular session. According to the same market data, Solomon Moshkevich was named chief executive in place of Steve Chapman. The Earnings release made no reference to any leadership change, and no company filing confirming it was located, so the item stays reported and unconfirmed. Natera sells blood tests that analyze cell-free DNA for prenatal screening, transplant monitoring and detection of cancer recurrence. Greater test Volume spreads fixed laboratory and sales expenses across more tests, which supports margins. Key risks are the leadership transition, reimbursement decisions, rivalry in cancer monitoring and thin after-hours trading that may reverse.

Amylyx Pharmaceuticals (NASDAQ:AMLX): Repeated Trial Data Carries an Older Date

The 55% finding is not new information. Amylyx Pharmaceuticals (NASDAQ:AMLX) first disclosed the topline outcome on August 18, 2026 and brought the figure forward in its third-quarter release dated November 5. The Phase 3 LUCIDITY study enrolled 78 adults with post-bariatric hypoglycemia, a disorder in which blood glucose drops too low after meals following weight-loss surgery. Participants were randomized in a 3 to 2 ratio to 90 mg of avexitide taken daily by injection or to placebo, and the company cited a p-value of 0.000003. The company said the study hit its primary endpoint and every secondary endpoint, with no serious adverse events tied to the drug. The FDA granted Breakthrough Therapy Designation, a status that can accelerate review without ensuring approval. At September 30, 2026, the company held USD 768.1 million across cash, equivalents and marketable securities, after collecting roughly USD 544.6 million net from an August public offering. Losses widened, with the quarter's net figure at USD 45.5 million, or USD 0.38 per share, as trial costs and launch readiness spending climbed. The study was small and lasted 16 weeks, so regulators will weigh how durable the effect is. The findings head to ObesityWeek for presentation on November 15, 2026, and a verified share price reaction is not available.

Oscar Health (NYSE:OSCR): Operating Earnings Outlook Rises for a Third Time

Oscar Health (NYSE:OSCR), a health insurer concentrated on individual and ACA marketplace coverage, published its third-quarter 2026 numbers on November 5, 2026. It lifted full-year earnings from operations to USD 850 million through USD 950 million from USD 600 million through USD 800 million. The revenue outlook was also raised, now placed between USD 19.0 billion and USD 19.3 billion. Quarterly revenue rose to USD 5.139 billion from USD 2.99 billion twelve months before, and that total is inflated by USD 250 million from revised risk-adjustment estimates, a transfer from regulators that may reverse. Net income came to USD 167.3 million, or USD 0.49 per diluted share, compared with a loss a year earlier. The medical loss ratio, the portion of premiums paid out as claims, fell to 84.0% from 88.5%, while the SG&A ratio dropped to 14.0% from 17.5%. Effectuated membership was 2,691,885, roughly 27% above a year earlier (own arithmetic). The company pointed to risks from expiring enhanced premium tax credits and 2027 payment rules, though it did not quantify them, and it projected share gains and wider margins for 2027, which is its own expectation. Whether the stock moved on the release has not been verified.

Where Things Stand

Not on the evidence reviewed, since each move had a separate cause. Veracyte (NASDAQ:VCYT) appears to have fallen on a lower testing outlook and slower Decipher growth despite 15% revenue expansion, and the 54.30% reading comes from one listing alone. Natera (NASDAQ:NTRA) slid after hours, most likely on the reported leadership change, though that is an inference because the release is silent on it. Amylyx Pharmaceuticals (NASDAQ:AMLX) presented data it had already reported, and no share move has been verified. Oscar Health (NYSE:OSCR) lifted its outlook, but risk-adjustment items and Subsidy rules muddy 2027. The shared thread is that outlook and governance news weighed more than headline growth. Watch next for Decipher volumes, any filing on Natera's leadership, the November 15 ObesityWeek session and Oscar's open enrollment. None of this is a forecast.